$MDLN

GIC Private Ltd sold 2,248,612 shares of Medline Inc. (MDLN) at an average of $35.56 ($35.33–$36.48, $79.97M total) across 3 trades over 2026-08-05 to 2026-08-06.

Truist Securities adjusted its price target for Medline Inc. to $47 from $56 while maintaining a Buy rating, according to the report. The stock is shown at $36.66, down 12.79% over five days and 8.52% year to date as of the article’s market data.

DENTSPLY SIRONA (XRAY) said Medline Sinclair will expand distribution of its full technology portfolio across Canada starting Sept. 1, 2026, broadening a prior consumables-focused partnership. The company expects this could help scale digital dentistry solutions. Investors also look to its Aug. 6 Q2 2026 results and guidance on transformation spending and demand pressures.

Simply Wall St reports Medline (MDLN) shares fell nearly 13% after Q2 results. Revenue rose to about $7.7b (+11.6%), but net income excluding items dropped to $60m from $333m. Adjusted EBITDA was about $1.06b with a reported margin boosted by a $243m tariff refund, while full-year EBITDA guidance was cut to $3.3–$3.4b amid margin pressure and unresolved FDA/legal issues.

Medline (MDLN) reported Q2 2026 adjusted EBITDA of $817 million, beating consensus, and discussed guidance impacts. The CFO said incremental earnings impact from inflationary pressure is split between transitory and permanent factors, with $200 million incremental costs and $243 million net tariff refunds excluded from adjusted EBITDA guidance. Organic growth was 9% to 10%, and signings were $650 million YTD.

Gold rose 4% to $4,233.89 an ounce and silver gained 3.9% to $61.85 after ADP reported 44,000 private jobs added in July and ISM Services PMI employment fell. The Dow rose 0.9% to 54,545 and the S&P 500 held near 7,739. Newmont jumped 7.3%; Freshpet, Dynatrace, Aura Minerals, and Primo Brands rose, while DaVita, Medline, and Regal Rexnord fell.

Medline (NASDAQ:MDLN) reported Q2 sales growth across segments: Surgical Solutions $1.6B (+9%), Frontline Care $1.7B (+4%), Lab and Diagnostics $248M (+12%), and Supply Chain Solutions $4.1B (+16%). Adjusted EBITDA rose 13% to $1.1B, including $243M IEEPA tariff refunds. Medline raised organic sales guidance to 9%-10% but cut adjusted EBITDA to $3.3B-$3.4B.

Medline (MDLN) shares fell 11.4% in pre-open trading after reporting Q2 2026 results. The company cited profitability and cost pressures, following Q1 net income down 25.8% and Adjusted EBITDA down 10.6% with 250 bps margin compression tied to tariff costs and investments. UBS cut its price target to $50 from $57, and the COO announced retirement.

Medline Inc. (MDLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9912q26pressrelease.htm EX-99.1 Document August 5, 2026 Medline Reports Second Quarter and First Six Months 2026 Results • Second quarter net sales of $7.7 billion, an increase of 11.6% • Second quarter net income of $139 million, a decrease of 58.3% • Second quarter

Medline (Nasdaq: MDLN) plans to open a new roughly 1 million-square-foot distribution center in Perris, California, to add capacity and supply-chain flexibility. The move follows a June 11 fire at its Tracy, CA center and a July 6 announcement securing 1.6 million square feet in Northern California, with the CA footprint nearing 5 million square feet by mid-2027.